Ascendia Pharmaceuticals Revenue and Competitors

North Brunswick, NJ USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Ascendia Pharmaceuticals's estimated annual revenue is currently $13.5M per year.(i)
  • Ascendia Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Ascendia Pharmaceuticals has 67 Employees.(i)
  • Ascendia Pharmaceuticals grew their employee count by 18% last year.

Ascendia Pharmaceuticals's People

NameTitleEmail/Phone
1
SVP Business DevelopmentReveal Email/Phone
2
Head Quality AssuranceReveal Email/Phone
3
Senior Director Scientific Affairs and Technical MarketingReveal Email/Phone
4
Director Engineering and FacilitiesReveal Email/Phone
5
Chief Business OfficerReveal Email/Phone
6
Director Project ManagementReveal Email/Phone
7
Director Quality AssuranceReveal Email/Phone
8
Senior DirectorReveal Email/Phone
9
Office ManagerReveal Email/Phone
10
Senior Director Business DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Ascendia Pharmaceuticals?

Based in North Brunswick, New Jersey, Ascendia Pharmaceuticals is a specialty contract development and manufacturing (CDMO) company dedicated to delivering sophisticated formulations of existing drug products, and enabling formulations for preclinical- and clinical-stage drug candidates. Ascendia Pharmaceuticals is your ideal partner for: · Early stage IND-enabling formulations for toxicology and pharmacokinetic (PK) studies · Rapid development through Phase I CTM materials for oral and parenteral dosage forms · Fast discovery formulation support · Formulation development and CTM manufacturing for specialty pharmaceuticals Ascendia Pharmaceuticals also provides special development programs: · Formulations for poorly soluble and low bioavailability drugs · First-in-man injectable formulations · Nano-emulsion and nano-particle formulations · Peptide formulations · Sustained release by parenteral or oral routes · Development of 505(b)(2) products · Development of complex generics · High potency and DEA controlled drug substances · Ocular formulation development · Animal health formulations

keywords:N/A

N/A

Total Funding

67

Number of Employees

$13.5M

Revenue (est)

18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.1M7021%N/A
#2
$20.8M709%N/A
#3
$11M7129%N/A
#4
$9.4M72-1%N/A
#5
$14.9M7410%N/A